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Background: Cytolytic T lymphocytes (CTL) and natural killer (NK) cells have been implicated as important cells in
antitumor responses. Our previous research has shown that high mobility group nucleosomal-binding domain 2
(HMGN2) could be released by IL-2 and PHA stimulated peripheral blood mononuclear cells (PBMCs) and also
induced tumor cells apoptosis at low doses. In this study, we isolated and cultured PBMCs and CD8+ T cells to
analyze the expression and antitumor effects of HMGN2.
Methods: PBMCs from healthy donors were isolated using Human Lymphocyte Separation tube. CD8+ T cells were
separated from the PBMCs using MoFlo XDP high-speed flow cytometry sorter. Activation of PBMCs and CD8+ T
cells were achieved by stimulating with Phytohemagglutinin (PHA) or tumor antigen. In addition, the methods of
ELISA, intracellular staining, and fluorescence-labeling assays were used.
Results: PHA induced PBMCs to release high levels of HMGN2, and CD8+ T cells was the major cell population in
PBMCs that release HMGN2 after PHA activation. Tumor antigen-activated CD8+ T cells also released high levels of
HMGN2. Supernatants of tumor antigen-activated CD8+ T cells were able to kill tumor cells in a dose-dependent
manner. This antitumor effect could be significantly blocked by using an anti-HMGN2 antibody. Fluorescence-labeling
assays showed that the supernatant proteins of activated CD8+ T cells could be transported into tumor cells, and the
transport visibly decreased after HMGN2 was depleted by anti-HMGN2 antibody.
Conclusions: These results suggest that HMGN2 is an anti-tumor effector molecule of CD8+ T cells.
Keywords: HMGN2, PMBC, CD8+ T cells, Antitumor activity, Anti-tumor effector moleculeBackground
Cytolytic T lymphocytes (CTLs) and Natural killer (NK)
cells function as antitumor immune cells. CTLs and NK
cells are rich in cytoplasmic granules. Upon degranulation,
these cells release cytotoxic substances that act on target
cells [1]. Granules in the cytoplasm of CTL contain per-
forin, granzymes, granulysin, additional effector molecules
involved in the antitumor response and several uncharac-
terized components [2-5].
Previously, we isolated and purified an antimicrobial
polypeptide from interleukin (IL)-2 and PHA stimulated
human peripheral blood mononuclear cells (PBMCs) and
identified the polypeptide as high mobility group nucleo-
somal binding domain 2 (HMGN2). When cultured PBMCs
were stimulate with IL-2 and PHA, HMGN2 was expressed* Correspondence: pingzhang68@hotmail.com; 953463551@qq.com
State Key Laboratory of Oral Diseases, West China College of Stomatology,
Sichuan University, Chengdu, Sichuan, China
© 2014 Su et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.in the cytoplasm and then released into the supernatant
[6]. HMGN2 is one of the most abundant non-histone nu-
clear proteins of vertebrates and invertebrates [7], and is a
highly conserved nucleosomal protein thought to be in-
volved in unfolding higher-order chromatin structures
and facilitating transcriptional activation of mammalian
genes [7]. However, until now, the biological role of this
protein has not been fully defined, and some new re-
search results have revealed that the protein has add-
itional functions.
In this study, we isolated and cultured human PBMCs
and separated CD8+ T cells from PBMCs. PBMCs and
CD8+ T cells were then activated by PHA or tumor anti-
gen (T-Ag), followed by analysis of HMGN2 protein ex-
pression and release. Our results showed that activated
CD8+ T cells express high levels of HMGN2 protein,
and HMGN2 protein in the culture supernatant of acti-
vated CD8+ T cells had proved had anti-tumor effect.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PHA-activated T cells released high levels of HMGN2
PHA is a lectin found in plants, especially legumes, and
is a mitogen that triggers T-lymphocyte cell division and
activation. Supernatants of PBMCs that have been stim-
ulated by PHA contain a series of effector proteins. In
our experiments, PBMCs were isolated from healthy do-
nors and stimulated with 20 μg/ml PHA or 100 IU/ml
IL-2 for 72 hours. Supernatants were collected and
HMGN2 concentrations were analyzed by ELISA. The
results showed that PBMCs release high levels of HMGN2
(771.33 ± 123.12 ng/ml) following 20 μg/ml PHA stimu-
lation for 72 hours. Compared with the medium control
(289.67 ± 98.5 ng/ml) and IL-2 stimulated (397.67 ±
134.15 ng/ml), HMGN2 concentration significantly in-
creased (Figure 1A). In order to make sure that HMGN2
was released by activated T cells, we used surface and
indirect intracellular staining to analyze HMGN2 ex-
pression in CD3+ T cells. Consistent with the ELISA re-
sults (Figure 1A), compared with the medium control
(9.06 ± 3.8%) and IL-2 stimulated (18.85 ± 8.71%), the per-
















































Figure 1 PHA induced HMGN2 expression in PBMCs. PBMCs were seed
20 μg/ml PHA or 100 IU/ml IL-2 for 72 hours. Normal medium was used as the
were analyzed by ELISA. (B) The cells were removed and stained with anti
coulter FC500 Flow cytometry. Data were analyzed by using Submit 5.2 so
are representative of three independent experiments. (C) Error bars repres
Data are represented as means ± SD of three independent experiments. *Signifi
plots of the isotype staining and 2nd-Ab-FITC staining control.increased after PHA stimulation (47.79 ± 11.87%) (Figure 1B
and C).
HMGN2 was highly expressed in activated CD8+ T cells
To determine which T cell population expressed HMGN2,
we stained the PHA pre-activated PBMCs with CD4-PE
or CD8-PE surface staining. We then stained intracellular
HMGN2 with rabbit anti-human HMGN2/goat anti-
rabbit IgG-FITC. Results showed that HMGN2 expression
significantly increased in both CD4+ and CD8+ T cell pop-
ulations (Figure 2A, B, C). In addition, HMGN2 expres-
sion in CD8+ T cells (50.71 ± 10.34%) was significantly
higher than that in CD4+ T cells (16.67 ± 5.61%) after
PHA stimulation (Figure 2D). Finally, we used a MoFlo
XDP high-speed flow cytometry sorter to purify PHA pre-
activated CD3+CD8+ T cells, CD3+CD8− T cells and CD3−
mix cells, followed by culturing in complete medium with
2000 IU/ml IL-2 for 5 days and analyzed the expression of
HMGN2 by ELISA and intracellular staining. Results
showed that HMGN2 was still expressed at high levels in
CD8+ T cells (539.00 ± 118 ng/ml; 68.37 ± 15.21%). On the





















ed at a density of 1 × 107 per well in 6 well plates and stimulated with
control. (A) The supernatants were collected and HMGN2 concentrations
-CD3-PE and anti-HMGN2-IgG-FITC, followed to run on a Beckman
ftware after gate lymphocytes (R5) group on dot plot graph. Figures
ent HMGN2 intracellular expression positive rate (%) in CD3+ T cells.
cantly higher compared to medium control (p < 0.05). (D) Representative
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Figure 2 PHA induced HMGN2 expression in different cell populations. PBMCs were seeded at a density of 1 × 107 per well in 6 well plates
and stimulated with 20 μg/ml PHA or 100 IU/ml IL-2 for 72 hours. Normal medium was used as the control. Cells were collected and stained (A)
Anti-CD4-PE surface stained and anti-HMGN2/IgG-FITC intracellular stained; (B) Anti-CD8-PE surface stained and anti-HMGN2/IgG-FITC intracellular
stained. Figures are representative of three independent experiments. (C, D) Error bars represent HMGN2 intracellular expression positive rate (%)
in CD4+ or CD8+ T cell populations. Data are represented as means ± SD of three independent experiments. *Significantly higher compared to
IL-2 and medium control (p < 0.05), #Significantly higher compared to CD4+ T cell population (p < 0.05). (E) Representative plots of the isotype
staining and 2nd-Ab-FITC staining control.
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11.52%) and the CD3− mixed PBMCs population (386.67 ±
105.46 ng/ml; 35.73 ± 13.71%) was significantly lower in
both supernatants and intercellular (Figure 3A, B and C).
These results confirmed that activated CD8 +T cells
expressed high levels of HMGN2.
Tumor antigen activated CD8+ T cells expressed high
levels of HMGN2
In order to ensure that HMGN2 was an effector protein
of tumor antigen activated T cells, we used tumor full
protein as tumor antigen (T-Ag) to stimulate PBMCs for
7 days. Supernatants were collected for assaying HMGN2
levels by ELISA and cells were collected for HMGN2
intracellular staining. Results showed that there was no
significant change of HMGN2 expression after stimulation
with T-Ag compared with the medium control (Figure 4).In order to ensure that T cells were activated by T-Ag, we
used CD44high as the activated marker of T cells. T-Ag
stimulated PBMCs were stained with CD8-PE/CD44-APC
surface and HMGN2 indirect intracellular staining.
CD44high was used as the activated T cell population
(Figure 5Aa, gate R2) and CD44low was used as the
naive T cell population (Figure 5Aa, gate R6). T-Ag in-
duced only 18.35 ± 6.20% PBMCs activated (Figure 5Aa,
gate R2 and 5B). There was about 43.69 ± 12.51% of acti-
vated CD8+ T cells expressed HMGN2 (Figure 5Ab and
C), where only 18.71 ± 6.34% naive CD8+ T cells expressed
HMGN2 (Figure 5Ac and C).
We used a Beckman Coulter MoFlo XDP high-speed
flow cytometry sorter to isolate T-Ag-activated the
CD44highCD8+ T cell population (Figure 6A, Gate R4).
The purified cells were cultured with 2000 IU/ml IL-2 for
























































Figure 3 PHA-induced HMGN2 was mainly expressed in CD8+ T cell population. PBMCs were seeded at a density of 1 × 107 per well in 6
well plates and stimulated with 20 μg/ml PHA for 72 hours. Cells were collected and stained with CD3-FITC and CD8-PE. CD3+CD8+T cells (Gate
R1), CD3+CD8−T cells (Gate R2) and CD3− mixed cells (Gate R3) were purified with MoFlo XDP sorter. 4 × 106 CD3+CD8+T cells, CD3+CD8−T cells
and CD3− mixed cells were incubated in 24-well plates respectively for 5 days. (A) The supernatants were collected and HMGN2 concentrations
were analyzed by ELISA. (B) The cells were removed and intracellularly stained for HMGN2. Figures are representative of three independent experiments.
(C) Error bars represent HMGN2 intracellular expression positive rate (%) in CD8+ T cells populations. Data are represented as means ± SD of
















Figure 4 HMGN2 expression in Tumor antigen stimulated PBMCs. PBMCs were seeded at a density of 1 × 107 per well in 6 well plates and
stimulated with 150 μg/ml T-Ag for 7 days. Normal medium was used as the control. (A) The cells were removed and intracellularly stained for
HMGN2. Figures are representative of three independent experiments. (B) Error bars represent HMGN2 intracellular expression positive rate (%) in
PBMCs after stimulation with T-Ag. (C) The supernatants were collected and HMGN2 concentrations were analyzed by ELISA. Data are represented
as means ± SD of three independent experiments.





























































Figure 5 T-Ag activated T cells and induced HMGN2 expression in activated T cell populations. PBMCs were seeded at a density of 1 × 107
per well in 6 well plates and stimulated with 150 μg/ml T-Ag for 7 days. Normal medium was used as the control. Cells were removed and (A) stained
with CD44-APC/CD8-PE/intracellular HMGN2-2nd-Ab-FITC. (Aa) Gate 1 (CD44high) as the activated T cells, gate R6 (CD44low) as the naïve T cells. (Ab-Ac)
Intracellularly expression of HMGN2 in CD44high activated CD8+ T cells (Ab) and CD44low naïve CD8+ T cells (Ac). (B) Error bars represented the
percentage of activation PBMCs after stimulated with T-Ag. (C) Error bars represented HMGN2 intracellular expression positive rate (%) in T-Ag-activated
CD8+T cell populations. Data are represented as means ± SD of three independent experiments. *Significantly higher compared to medium control




















































Figure 6 T-Ag activated CD8+T cells released HMGN2 to kill tumor cells. PBMCs were seeded at a density of 1 × 107 per well in 6 well plates
and stimulated with 150 μg/ml T-Ag for 7 days. (A) Cells were removed and stained with CD44-APC/CD8-FITC. CD44high/CD8+T activated T cells
(Gate R4) were purified with MoFlo XDP sorter. The purified CD44high/CD8+T cells were cultured in complete medium with 2000 IU/ml IL-2 for
5 days. (B) The cells were removed and stained with Anti-CD8-PE surface stained and anti-HMGN2/IgG-FITC intracellular stained. (C) The antitumor
effects of the supernatants at different concentration. (D) The antitumor effects of the 20% (v/v) supernatants after blocking HMHN2 using anti-HMGN2
antibody. Figures are representative of three independent experiments. Data are represented as means ± SD of three independent experiments.
*Significantly decreased compared to medium control (p < 0.05). #Significantly decreased after with anti-HMGN2 antibody (p < 0.05).
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and stained with CD8-PE surface and HMGN2 intracellu-
lar staining. A total of 69.35 ± 12.13% of CD8+ T cells still
expressed HMGN2 (Figure 6B).
HMGN2 as an anti-tumor effector molecule of CD8+ T
cells
Tca8113 cells were seeded at a density of 1 × 103 cells
per well in 96-well plates. After overnight growth, the
medium was replaced with maintenance medium contain-
ing the desired concentrations (v/v) of T-Ag activated
CD8+ T cell supernatants. To one group, anti-HMGN2
antibody (10 μg/ml) was added, in order to block HMGN2.
Human HMGN2 protein was used as the positive control,
and the same volume of normal medium as the negative
control. Cell viability was assessed after 72 hours using the
CCK8 colorimetric assay. The supernatant was able to kill
tumor cells in a dose-dependent manner; 20% supernatant
could significantly kill tumor cells, as could the HMGN2
positive control (Figure 6C). The effect of killing tumor
cells by the supernatant could be significantly inhibited by
the anti-HMGN2 antibody (Figure 6D).
HMGN2 protein could transmembrane transported into
tumor cells
To confirm that the HMGN2 in the supernatant of T-Ag
activated CD8+ T cells could be transmembrane trans-
ported into tumor cells, we used fluorescence FITC to
label the proteins in the supernatant, before adding to
the medium. Human FITC labeled HMGN2 protein was
used as the positive control. Results showed that the
protein in the supernatant could effectively be transported
into the tumor cells, as could the human HMGN2 protein
control (Figure 7A, Figure 7B b&e, Figure 7C b&d). After
HMGN2-depleted by anti-HMGN2, the number of FITC-
positive cells visibly decreased comparing with HMGN2
undepleted samples analyzed by both fluorescent
microscope (Figure 7B b vs c, e vs f ) and Flow Cytome-
try (Figure 7C b vs c, d vs e).
Discussion
High mobility group (HMG) proteins have been described
to be an abundant family of nonhistone proteins in cell
nucleus of vertebrate and invertebrate organisms [7]. The
HMG protein family is subdivided into three subfamilies:
HMGB, HMGA and HMGN. Each subfamily appears to
exert a single characteristic nuclear function [7]. However,
peptides in the HMG protein family also exhibit adjunct
roles. For example, HMGbox1 (HMGB1) is an abundant,
highly conserved cellular protein, widely known as a nu-
clear DNA-binding protein [8,9]. A decade-long search has
culminated in HMGB1 as a late toxic cytokine of endotox-
emia. HMGB1, released by macrophages upon exposure to
endotoxin, activates a number of other proinflammatorymediators and is lethal to otherwise healthy animals [8,9].
And, HMGB proteins 1, 2 and 3 had been found function
as universal sentinels for nucleic-acid-mediated innate im-
mune responses [10].
The HMGN family includes five chromatin architec-
tural proteins that are present in higher vertebrates [11].
Of these proteins, HMGN1, 2, and 4 are expressed ubiqui-
tously [12,13], whereas HMGN3 and 5 are expressed in
specific tissues [14,15]. Initially, HMGNs were regarded as
transcription co-regulators; their roles in DNA repair and
cancer progression have, however, recently been estab-
lished. Recent studies suggest that the archetype of
HMGN1 has characteristics of a tumor suppressor gene
[16]. In addition to HMGN1, the expression of HMGN5
(formerly NSBP1) was found to be elevated 4-fold in
highly metastatic breast cancer cells compared with that
in low metastatic cells [17]. In mice, overexpression of
HMGN5 in the uterus was associated with the develop-
ment of uterine adenocarcinoma [18,19]. These studies
are consistent with the involvement of HMGN5 in can-
cer progression.
The HMGN2 gene is located at chromosome 1p36.1
and contains six exons [20], with an extremely high GC
content and an “HpaII tiny fragment” island. These hall-
marks are indicative of a housekeeping gene that may
be crucial to the basal functioning of cells [7]. However,
biological role of this protein has been poorly defined.
HMGN2 is preferentially associated with chromatin
subunits [7], and abnormal HMGN2 gene or protein ex-
pression is associated with development of neoplasms
and autoimmune diseases [21,22]. Porkka et al. [23] exam-
ined phage-displayed cDNA libraries in vivo to search for
phages capable of homing to the vascular endothelia of tu-
mors. This revealed a remarkably potent homing peptide,
F3, which corresponded to a 17–48 amino acid fragment
in HMGN2. The 31-residue peptide was shown to select-
ively bind to tumor cells both in vitro and in vivo. And
our previous showed that HMGN2 significantly inhibits
the growth of Tca8113 cells, adenoid cystic carcinoma
cell-2 line (ACC-2), human lung adenocarcinoma epithe-
lial cell line A549 and bladder cancer cell line T24, which
acted by promoting apoptosis in vitro and in vivo [24,25].
CTLs and NK cells are rich in cytoplasmic granules.
Following degranulation, the cells release specific bio-
logically active substances, which have a cytotoxic effect
on target cells [1]. The granules in the cytoplasm of
CTL contain perforin, granzymes, granulysin and other
effector molecules involved in the anti-tumor effect, as
well as certain unidentified components [2,3]. In our
previous study [6], we found that HMGN2 is released by
PBMCs in the presence of IL-2 and PHA. HMGN2 may
represent an effector molecule for CTL or NK cells.
In the present study we isolated and cultured PBMCs
and separated CD8+ T cells from PBMCs. PBMCs and




























































Figure 7 (See legend on next page.)
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Figure 7 HMGN2, released by T-Ag activated CD8+ T cells, transmembrane transported into tumor cells. HMGN2 protein and the
supernatant of T-Ag activated CD8+ T cells were pre-labeled with FITC. Tca8113 cells were seeded at a density of 3 × 104 per well in
24-well plates. After overnight growth, the cells were cultured in medium with FITC pre-labeled samples. (A) HMGN2 transport into
tumor cells analyzed with fluorescence microscope. The three figures are the same area. (a) Light micrographs of Tca8113 cells. (b)
Fluorescent micrographs of Tca8113 cells of Hoechst 33258 nuclear staining. (c) Fluorescent micrographs of FITC labeled HMGN2
protein distribution in Tca8113 cells. (B) The Tca8113 cells were analyzed with fluorescent microscope. (a, b, c) FITC pre-labeled HMGN2 as the positive
control. (d, e, f) FITC pre-labeled CD8+ T cells supernatant. (a, d) Cells under a light microscope. (b, e) Cells under a fluorescent microscope. (c, f) Cells
under a fluorescent microscope after cultured in medium with HMGN2 depleted samples. (C) The Tca8113 cells were analyzed with Flow Cytometry.
(a) Untreated Tca8113 control. (b, d) Tca8113 cultured in medium with FITC labeled samples. (c, e) Tca8113 cells cultured in medium with
HMGN2 depleted samples. Figures are representative of three independent experiments. (f) Error bars represent FITC positive rate (%) of
Tca8113 cells after cultured in medium with FITC labeled or HMGN2 depleted sample for 1 hour. Data are represented as means ± SD of three
independent experiments. *Significantly decreased compared to HMGN2 undepleted (p < 0.05).
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gen, followed by analysis of HMGN2 protein expression
and release. Our results demonstrated an enhanced ex-
pression of HMGN2 protein in activated T cells, especially
in activated CD8+ T cells. In addition, the supernatants of
activated CD8+ T cells were able to kill tumor cells in a
dose-dependent manner, and the tumor-killing effect of
the supernatant could be significantly inhibited by anti-
HMGN2 antibody. Fluorescence-labeling assays showed
that HMGN2 in the supernatant of activated CD8+ T cells
could be significantly transported into tumor cells. Our re-
sults suggest that HMGN2 is an anti-tumor effector mol-
ecule of CD8+ T cells.
Conclusions
HMGN2 protein was enhanced express in activated T
cells, especially in activated CD8+ T cells. In addition,
HMGN2 protein in the culture supernatant of activated
CD8+ T cells had antitumor effects. These results suggest
that HMGN2 is an anti-tumor effector molecule of CD8+
T cells.
Methods
Preparation of T-Ag, activated T cells, and the cell culture
supernatants
The human tongue squamous cell carcinoma cell line
Tca8113 cells were obtained from the State Key Labora-
tory of Oral Disease (Sichuan University, Chengdu,
China). Cells were cultured in RPMI 1640 medium sup-
plemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml
streptomycin, 3% L-glutamine, and 7.5% sodium bicarbon-
ate (GIBCO Life Technologies). Cells were maintained as
a monolayer in 25 cm plastic tissue culture flasks at 37°C
in a humidified atmosphere containing 5% CO2. Tumor
full protein (Tumor antigen, T-Ag) was prepared by lysing
Tca8113 cells in PBS, the lysate was collected and stored
at −80°C as T-Ag.
PBMCs from healthy human donors were isolated using
Human Lymphocyte Separation tube (Beijing DakeweBiotech Company Limited, China). PBMCs were plated
at a density of 1 × 107/well in six-well plates and cultured
in RPMI 1640 medium containing 10% fetal bovine serum,
100 IU/ml penicillin, and 100 μg/ml streptomycin). The
cells were stimulated with 150 μg/ml T-Ag for 7 days, or
20 μg/ml Phytohemagglutinin (PHA, Sigma, USA), 100 IU/
ml IL-2 for 72 hours to activate T lymphocytes. Superna-
tants were collected and HMGN2 concentration was ana-
lyzed, along with its effect on tumor cell survival. Cells
were removed to analyze HMGN2 expression by intracel-
lular staining.
Purifying T cell populations by flow cytometric sorting
PHA stimulated PBMCs were stained with CD8-PE/
CD3-FITC at 4°C for 30 minutes. Cells were washed
three times with sterilized PBS. The CD8+CD3+T cells,
CD8−CD3+T cells, and CD3− Mix cells populations were
gated and isolated using MoFlo XDP high-speed flow cy-
tometry sorter (Beckman). The purified T cell popula-
tions were cultured in complete medium with 2000 IU/
ml IL-2 for 5 days. Cells were collected for analyzing
HMGN2 expression.
T-Ag-stimulated PBMCs were stained with CD8-
FITC/CD44-APC at 4°C for 30 minutes. CD44highCD8+
cells were gated as the activated CD8+ T cell population.
CD44highCD8+ activated CD8+ T cells were isolated using
a MoFlo XDP high-speed flow cytometry sorter (Beckman).
The purified T cells were cultured in complete medium
with 2000 IU/ml IL-2 for 5 days. Supernatants and cells
were collected for analyzing anti-tumor effect and
HMGN2 expression.
ELISA analysis of HMGN2 concentration in the
supernatant
ELISA plates were coated with 100 μl of supernatants,
standards made from different concentrations of human
HMGN2 protein, or PBS (negative control). The plates
were left at 4°C overnight. After washing three times
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antibody (Proteintech Group, USA) (1:500) were added
and plates were incubated at 37°C for 1 hour. Then,
100 μl of HRP-conjugated anti-rabbit IgG secondary
antibody (1:1000) were added after thorough washing of
the first antibody, and plates were incubated at 37°C for
1 hour. Add 100 μl TMB substrate solution to each well.
After 20 min incubation, reactions were stopped with
2 N H2SO4 and measured at 490 nm in an ELISA plate
reader (VARIOSKAN FLASH, Thermo Fisher Scientific,
Vantaa, Finland).Intracellular staining analysis of HMGN2 expression by
flow cytometry
PHA or T-Ag stimulated PBMCs or purified T cell popula-
tions were collected and stained with fluorescence-labeled
CD4, CD8, or CD44 surface marker or msIgG-PE/FITC
isotypes (Biolegend, USA) control. After washing three
times with wash buffer, cells were analyzed for HMGN2
expression by using an intracellular staining kit (Invitro-
gen, USA). Briefly, a volume of 100 μl fixation buffer was
added to fix cells, which were then left at 4°C overnight,
followed by washing with permeabilization buffer three
times in order to permeabilize cells. All of the samples
were divided into two tubes, rabbit-anti-human HMGN2
antibody (1 μg/ml) was added into one tube and the same
volume PBS was added into the other as the 2nd-Ab-
FITC control. The samples were incubated at 4°C for 1 hour.
The cells were washed three times with permeabilization
buffer and then incubated with goat anti-rabbit-IgG-FITC
secondary antibody (2nd-Ab-FITC) at 4°C for 1 hour. Finally,
the cells were washed with Flow Cytometry buffer and runed
on a Beckman coulter FC500 Flow cytometry. Dates were
analyzed by using Submit 5.2 software (Beckman Coulter,
USA) after gate lymphocytes group on dot plot graph.Anti-tumor effects of HMGN2 in the supernatant of
T-Ag-activated CD8+ T cells
Tca8113 cells were seeded at a density of 1 × 103 cells per
well in 96-well plates. After overnight growth, the medium
was replaced with maintenance medium containing the de-
sired concentrations (v/v) of supernatant of T-Ag-activated
CD8+ T cells. Human HMGN2 protein was used as the
positive control and medium as the negative control.
Blocking of HMGN2 was achieved by adding 10 μg/ml
anti-HMGN2 antibody to 20% (v/v) supernatants. Cell
viability was assessed after 72 hours using the CCK8
colorimetric assay. Briefly, the cells were washed with
300 μl of PBS, followed by incubation with 100 μl of
5 mg/ml CCK8 in RPMI 1640 at 37°C for 1 hour, and
quantified by measuring the optical absorbance (OA)
at 450 nm in a plate reader (VARIOSKAN FLASH,
Thermo Fisher Scientific, Vantaa, Finland).Fluorescence-labeled HMGN2 transmembrane
transported assay
Human HMGN2 protein (2 μg/ml) and the supernatants
of T-Ag activated CD8+ T cells were labeled with FITC.
Briefly, FITC was added to 2 mg/ml protein solution and
incubated for 5 hours at room temperature. The uncon-
jugated FITC was removed using a 3 kDa filter. Half of
these FITC-labeled samples were depleted of HMGN2
by using anti-human HMGN2 antibody adsorption in
96-well plates. Briefly, 10ug anti-human HMGN2 anti-
body was coated in 96-well plates at 4°C for overnight.
The free antibody was removed by washing the wells
with PBS three times. The FITC labeled samples were
added into the wells and incubated at 37°C for 1 hour.
The samples were collected and store at −80°C as the
HMGN2 depleted samples.
Tca8113 cells were seeded at a density of 3 × 104 per well
in 24-well plates. After overnight growth, 2 μg FITC-
labeled HMGN2, 20% (v/v) FITC-labeled CD8+ T cells
supernatants and the same volume HMGN2-depleted
samples were added to the mediums, respectively. Plates
were incubated at 37°C in a humidified atmosphere con-
taining 5% CO2 for 1 hour. Nuclear staining control of
Tca8113 cells was measured using Hoechst 33258 (Pro-
mega Corporation, Madison, WI, USA). Staining was per-
formed according to the manufacturer's instructions. Cells
were analyzed under a fluorescence microscope and pic-
tures were taken. Then, all the cells were removed with
0.25% trypsin and analyzed FITC positive cells on a Beckman
coulter FC500 using Submit 5.2 software. Untreated Tca8113
cells were used as the negative control.
Statistical analysis
All values were expressed as means ± SEM. Data were
analyzed by one-way analysis of variance (ANOVA)
followed by Bonferroni test. P < 0.05 was considered to
indicate a statistically significant difference.
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